Evidence review

PT-141 and NSAIDs: Evidence Review for Sexual/CNS Pathways During Anti-Inflammatory Use

Posted Jun 29, 2026 · Updated Jul 17, 2026 · 4 min read

What's breaking down if you have NSAIDs

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why PT-141 might help you

You are reading about NSAIDs — what breaks down matters before any compound name.
Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.

Why NSAIDs matters for you

Drug: NSAIDs
What it does: Suppress inflammation signal; may slow structural repair cascade.
Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

PT-141 → sexual / CNS arousal

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

Scientific sources catalogued (PubMed, trials, reviews): 4
Claims tagged human evidence: 3
Claims tagged preclinical (animal/lab): 1
Claims tagged anecdotal: 0
Reddit posts catalogued: 0
X posts catalogued: 0
Other anecdote sources (YouTube, Instagram, etc.): 0
Total sources in chain: 4

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.5 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (source s7)

Phase 3 RECONNECT trials results on efficacy endpoints.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder

Phase 3 RECONNECT trials results on efficacy endpoints.

2026-06-30 01:12s7 · #c626f41dd011

Bremelanotide (subcutaneous route) - Side effects & dosage (source s9)

Lists common side effects from prescribing information.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Bremelanotide (subcutaneous route) - Side effects & dosage

Lists common side effects from prescribing information.

2026-06-30 01:12s9 · #617708b92f32

Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder (source s10)

Review summarizing trial side effects.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder

Review summarizing trial side effects.

2026-06-30 01:12s10 · #1dd1a3180a4a

PT-141 for Men (source s11)

Clinical site summarizing trial adverse events.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

PT-141 for Men

Clinical site summarizing trial adverse events.

2026-06-30 01:12s11 · #fcdafe729951

Safety and limits

PT-141 side effects in trials include nausea (~40%), flushing, and headache with transient BP rise.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Evidence · 4 sources · swipe →chain fcdafe729951 · verify chain · provenance

1 / 4

PubMed.gov

Study

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder

Phase 3 RECONNECT trials results on efficacy endpoints.

2026-06-30 01:12s7 · #c626f41dd011

PubMed.gov

Study

Bremelanotide (subcutaneous route) - Side effects & dosage

Lists common side effects from prescribing information.

2026-06-30 01:12s9 · #617708b92f32

PubMed.gov

Study

Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder

Review summarizing trial side effects.

2026-06-30 01:12s10 · #1dd1a3180a4a

PubMed.gov

Study

PT-141 for Men

Clinical site summarizing trial adverse events.

2026-06-30 01:12s11 · #fcdafe729951

Evidence ledger 4 · tier-ranked · API

human

PT-141 side effects in trials include nausea (~40%), flushing, and headache with transient BP rise.

sources: s9, s10, s11

human

Two phase 3 RECONNECT trials showed PT-141 improved sexual desire scores and reduced distress versus placebo in premenopausal women with HSDD.

sources: s7

human

No human trials examine PT-141 with NSAIDs or test interactions.

preclinical

NSAIDs suppress inflammation signals and may slow tissue repair cascades in preclinical models.

Model review1 contributions · 1 modelExpand the recursive review layer

1 / 1

grok/grok-4.3writer

redraft2026-06-30 01:12

PT-141 and NSAIDs: Evidence Review for Sexual/CNS Pathways During Anti-Inflammatory Use · 4 claims · 4 sources

inspect — what it was prompted & output

prompted with

(default writer prompt)

input: Write a data-first, evidence-graded article: PT 141 for Nsaids
Slug: pt-141-nsaids
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_cross","condition":"NSAIDs","condition_key":"nsaids","primary_peptide":"pt-141","peptides_in_scope":[{"id":"pt-141","name":"PT-141"}],"drugs_in_scope":["nsaids"],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down if you have NSAIDs","deg

it output

{
  "slug": "pt-141-nsaids",
  "title": "PT-141 and NSAIDs: Evidence Review for Sexual/CNS Pathways During Anti-Inflammatory Use",
  "body": "## What's breaking down if you have NSAIDs\n\nNSAID use suppresses key inflammation signals that normally trigger tissue repair cascades. This can slow structural healing in muscles, tendons, joints, and the gut lining. Chronic or repeated dosing trades short-term symptom relief for potential delays in full recovery. In the repair-versus-degeneration frame, the drug reduces the signal load but may let breakdown outpace repair in load-bearing tissues or mucosal barriers. No direct degeneration profile matches the slug, so layers center on suppressed inflammatory resolution and possible secondary effects on sexual function or CNS arousal pathways through systemic stress or discomfort.\n\n## Why PT-141 might help you\n\n1. You are reading about NSAIDs — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts on melanocortin receptors in the central nervous system to influence sexual desire and arousal pathways. If NSAID-related inflammation or discomfort has layered into reduced sexual interest or CNS signaling fatigue, the compound's studied effect on those specific receptors offers a di

64c401ffa4339816

Machine verification: /api/articles/pt-141-nsaids/contributions

Ask this article · 6 suggested prompts

topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "PT-141 side effects in trials include nausea (~40%), flushing, and headache with transient BP rise."?

ask pt-141-nsaids claim c4 · paste includes §SELF

What does the ledger say about this (human tier): "Two phase 3 RECONNECT trials showed PT-141 improved sexual desire scores and reduced distress versus placebo in premenopausal women with HSD…"?

ask pt-141-nsaids claim c1 · paste includes §SELF

What does the ledger say about this (human tier): "No human trials examine PT-141 with NSAIDs or test interactions."?

ask pt-141-nsaids claim c2 · paste includes §SELF

What does the ledger say about this (preclinical tier): "NSAIDs suppress inflammation signals and may slow tissue repair cascades in preclinical models."?

ask pt-141-nsaids claim c3 · paste includes §SELF

For my medical situation, what can you answer from your catalogue about PT-141 and NSAIDs: Evidence Review for Sexual/CNS Pathways During Anti-Inflammatory Use — and what would you need me to tell you first?

ask pt-141-nsaids condition gaps · paste includes §SELF

What good and bad outcomes are documented for PT-141 and NSAIDs: Evidence Review for Sexual/CNS Pathways During Anti-Inflammatory Use (studies vs anecdotes)?

ask pt-141-nsaids good bad experiences · paste includes §SELF

What's breaking down if you have NSAIDs

Why PT-141 might help you

Why NSAIDs matters for you

How these fit together

What the evidence actually shows

What scientists say

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (source s7)

Bremelanotide (subcutaneous route) - Side effects & dosage (source s9)

Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder (source s10)

PT-141 for Men (source s11)

Safety and limits

Connected articles

Related articles